SV2A · Grey Matter

SV2A (synaptic vesicle glycoprotein 2A) is a protein in the membrane of the vesicles that store neurotransmitter, present in nearly every synapse of the brain, and it is the binding site of the antiseizure drugs levetiracetam and brivaracetam.

SV2A. SV2A (synaptic vesicle glycoprotein 2A) is a protein in the membrane of the vesicles that store neurotransmitter, present in nearly every synapse of the brain, and it is the binding site of the antiseizure drugs levetiracetam and brivaracetam.

Its exact job is still debated. Mice without SV2A develop severe seizures and die young, and synapses lacking it release transmitter less reliably, so it is needed for vesicles to be ready for calcium-triggered release; proposed roles include helping to prime vesicles, interacting with synaptotagmin, and transporting some still unidentified substance (its structure resembles a family of transporters). Its sister proteins SV2B and SV2C have a more restricted distribution, and SV2 is also the receptor that botulinum toxin A uses to enter nerve terminals.

Levetiracetam was found to stop seizures in animal models first, and SV2A was identified as its binding site afterwards; binding affinity across related compounds tracks their antiseizure potency, which is the main evidence that SV2A is the target.

Brivaracetam binds the same site with about 15 to 30 times higher affinity and more selectivity. Recent structures show both drugs sitting in a central cavity of the protein and holding it in one conformation.

How binding reduces seizures is a hypothesis: the drugs appear to reduce release mainly at synapses that are firing hard and repeatedly, while affecting normal transmission little. This activity dependence is the usual explanation for why they calm hyperactive circuits.

SV2A drugs work on supply.

They leave receptors and channels alone and act on the readiness of the vesicles themselves, so their effect grows with how hard a synapse is being driven.

Questions: How do levetiracetam and brivaracetam reduce seizures by binding SV2A? Both drugs bind the same pocket of SV2A, brivaracetam with about 15 to 30 times higher affinity, and across related compounds the strength of binding tracks antiseizure potency, which is the main evidence that SV2A is their target. The leading hypothesis is that binding reduces how many vesicles are ready for release, and that the effect shows mostly at synapses driven hard and repeatedly, as during the build-up of a seizure, while ordinary transmission changes little. The step from binding to fewer released vesicles is still being worked out, so the mechanism is best stated as a well-supported hypothesis. Where in the release machinery does SV2A sit, and what is it known to do? SV2A is a protein of the vesicle membrane itself, present on the vesicles of almost every synapse, beside synaptobrevin and synaptotagmin. Synapses without it release transmitter less reliably and mice lacking it have severe seizures, so it helps keep vesicles ready for calcium-triggered fusion. Its precise molecular job is still unsettled: it resembles a transporter, it interacts with synaptotagmin, and its substrate, if it has one, is unknown. Structures published in 2024 show where the antiseizure drugs and botulinum toxin A bind on it.